#### AN UPDATED COMPREHENSIVE REVIEW ON HYPERTENSION

<sup>1</sup>Manoj Singh Khanayat, <sup>2</sup>Meenakshi Kandwal, <sup>3</sup>Shivanand Patil

Research Scholar, Shree Dev Bhoomi Institute of education science and technology, Dehradun

Associate Professor, Shree Dev Bhoomi Institute of education science and technology, Dehradun

Professor, Shree Dev Bhoomi Institute of education science and technology, Dehradun

# Abstract

The prevalence of hypertension, which is a leading cause of cardiovascular morbidity and mortality on a global scale, continues to be a substantial obstacle for the public health sector. The purpose of this review article is to provide a comprehensive analysis of the pathophysiology, risk factors, and contemporary therapeutic techniques for hypertension. We explore the mechanisms that contribute to the onset of hypertension, which include genetic, environmental, and lifestyle factors within the context of our investigation. In this research, a variety of diagnostic approaches are investigated, with a particular focus on the significance of accurate blood pressure assessment and the role that ambulatory blood pressure monitoring plays. Comprehensive analysis is performed on pharmacological therapies, which include medicines such as calcium channel blockers, diuretics, angiotensin-converting enzyme inhibitors, and innovative drug groups. In addition, we incorporate non-pharmacological treatments such as dietary modifications, physical activity, and approaches for stress reduction. The analysis highlights the significance of customised treatment techniques as well as the challenges associated with achieving optimal blood pressure regulation across a wide range of patient demographics. In conclusion, novel drugs and ongoing research are investigated, with the goal of providing insights into potential future approaches to the treatment of hypertension.

Keywords: calcium channel blockers, diuretics, angiotensin-converting enzyme inhibitors, Hypertension

# Introduction

The condition known as systemic arterial hypertension, which will be referred to as hypertension from this point forward, is characterised by persistently high blood pressure in the systemic arteries.[1][2] The ratio of systolic blood pressure, which is the pressure that is imposed by blood on artery walls during cardiac contraction, to diastolic blood pressure, which is the pressure that is exerted during cardiac relaxation, is the standard equation that is used to express blood pressure (BP).[3][4][5] It is dependent on the method of measurement that is utilised to determine the blood pressure thresholds that define hypertension. [6]The condition known as hypertension can have a number of different causes. With a complicated genetic and environmental aetiology, approximately 90-95% of individuals have exceedingly heterogeneous 'essential' or primary hypertension. This type of hypertension is marked by a wide range of symptoms.[7] Heritability, which is an evaluation of the extent to which genetic variables contribute to trait variation, is estimated to be between 35 and 50 percent in the majority of investigations. Individuals who have hypertension are frequently found to have a favourable familial history. Genetic investigations known as genome-wide association studies (GWAS) have identified roughly 120 loci that are linked with the control of blood pressure. These loci combined account for 3.5% of the variance in the variable. [8][9][10] The fact that hypertension is a significant modifiable risk factor for cardiovascular diseases (CVD) makes it a significant contributor to the premature mortality and morbidity that occurs in the United States.1.2 Although the age-adjusted prevalence of hypertension has remained stable across the globe, the overall number has increased by a factor of two. This increase can be linked to an increasing tendency in low- and middle-income countries (LMICs) between the years 2000 and 2010.[11-15] In the year 2021, around 21% of hypertensive persons all across the world kept their blood pressure under control without any problems. Within the Indian population, hypertension is the most significant risk factor for both mortality and disability. In the most recent round of the National Family Health Survey (NFHS-5), which was conducted in 2019-2020,[16] the prevalence of hypertension was found to be 24% in men and 21% in women. This represents an increase from the 18% and 17%, respectively, that were found in the previous round. The National Program for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases, and

Stroke (NPCDCS) was officially launched in India in the year 2010, in response to the increasing prevalence of non-communicable diseases (NCDs). Subsequently, the program was expanded to cover the entire country by March of 2016.[17] Despite this, more than eighty percent of patients in India who seek medical attention from the private sector for non-communicable diseases are not included in the program. These patients are not exposed to active monitoring for the management of hypertension, which may include, but is not limited to, adherence to medication.[18-20] According to the numbers taken from the National Family Health Survey in 2015-16, fewer than eight percent of hypertension patients had their blood pressure under sufficient control[21]. An initiative called the India Hypertension Control Initiative (IHCI) was launched in 2017 as a collaborative effort between the Ministry of Health and Family Welfare of the Government of India, the Indian Council of Medical Research (ICMR), the WHO Country Office for India, and Resolve to Save Lives. The IHCI was launched in response to inadequate control rates and to enhance access to treatment services. [22][23]



Fig: 1 Disease associated by Hypertension

There is a causal relationship between decreased vasodilation capacity and increased blood pressure. Intake and excretion of fluids by the body are the two primary factors that determine the volume of intravascular fluid. When the fluid balance is disrupted, an increase in the volume of fluid that is found within the intravascular space can immediately lead to an increase in blood

pressure. Therefore, hypertension may be caused by variables that either increase the volume of blood in the body or decrease the capacity of the blood vessels to dilate. [24][25]The manifestation and progression of essential hypertension are often accompanied by the presence of several components, which are intricately connected to one another. At the moment, the creation of successful treatment programs for hypertension patients is made more difficult by the absence of appropriate clinical identification processes.[26][27] The use of pharmaceutical medication in conjunction with changes in lifestyle is the methodology that is most commonly employed for the management of hypertension. There are several single-pill combinations that have been produced from the three basic antihypertensive drugs, which are renin-angiotensin-aldosterone system (RAAS) inhibitors, [28][29]calcium channel blockers, and diuretics. These medications have been widely used to treat hypertension. There have been recent discoveries made on essential hypertension, which have provided significant theoretical data that may be used to improve both the understanding of the condition and the treatment of it. This review provides a concise analysis of recent developments in the pathophysiology of critical hypertension as well as therapeutic options for management of the condition. [30][31]

## Pathophysiology and historical concept

The mysterious aspects of primary hypertension and the particular mechanisms that contribute to high blood pressure, including cases of secondary hypertension and experimental hypertension models, [32][34]have been the subject of inquiry and investigation for more than a century. This includes the circumstances surrounding the development of hypertension. Ischemic or under perfused kidneys secrete a substance or compounds that are capable of rising blood pressure in recipient animals, according to the findings of first experiments conducted, which were later modified and reported. [35][36][37] They referred to this material as hypertensin and angiotonin, respectively. Finally, they came to an agreement that it should be referred to as angiotensin. Irvine Page is widely acknowledged as a pioneering figure in the field of hypertension research, and his accomplishments are both major and long-lasting. In the course of his preliminary experimental observations with Oscar Helmer, he discovered that when renin preparations were subjected to plasma that included what he referred to as "renin activator," a pressor material was produced. This pressor material had the ability to raise blood pressure to a level of 300 mmHg. He gave the name "angiotonin" to this biological substance. After careful consideration, one

might easily arrive to the conclusion that the sole cause of this rise in blood pressure was the considerable vasoconstriction. In spite of this, his further observations suggested that this explanation was less than adequate. In his important work from 1949,[38] he compiled information suggesting that hypertension may be impacted by the central nervous system, cardiovascular factors, endocrine variables, and renal function problems. Each of these components have the potential to influence hypertension."12" The findings that he presented suggested that the hypertension that was brought on by acute injections of "angiotonin" could be reduced by ganglionic blocking with the help of tetraethylammonium. According to the findings of a subsequent study conducted by Dr. Page and colleagues, [39] low rates of angiotensin II infusion had a negligible or nonexistent impact on blood pressure during the first few hours after the infusion. However, after twenty-four hours, blood pressure was elevated by thirty millimetres of mercury, indicating the significance of mechanisms that go beyond immediate vasoconstriction. The fact that he was able to recognise the "slow pressor" response to angiotensin was a big step forward in the field, and it has provided subsequent researchers with a good model of human hypertension.[40] In addition, he discovered that these infusions of lowdose angiotensin II led to very unstable blood pressure, which meant that even relatively minor environmental triggers caused large rises in blood pressure, which were accompanied by an increased heart rate. Tyramine, which increases the release of norepinephrine from nerve terminals, was responsible for the intensification of the blood pressure rises, whereas guanethidine, which inhibits the release of norepinephrine, was responsible for the inhibition of the blood pressure elevations. [41][42] The researchers came to the conclusion that "angiotensin induces hypertension through an indirect mechanism facilitated by the central nervous system, a process independent of its vasoconstrictive effects." This conclusion was reached as a result of conducting these extensive studies.[43] in total He observed that the levels of renin did not increase during the chronic phase of multiple cases of human hypertension. Based on this observation, he deduced that human hypertension has complex origins, which suggests that it is most likely caused by a combination of factors. He chose to define this multifactorial nature with the word "Mosaic" in his study that was conducted in 1949. [44]He emphasised that [45]numerous mechanisms are variably engaged." Because of the numerous forces that are applied to the various tissues that make up the circulatory system, an elevated blood pressure is the result. During a subsequent review, Dr. Page presented a now-iconic octagonal diagram

(Figure 2A). [46] This diagram has been modified and reproduced numerous times to illustrate his assertion that hypertension is caused by a number of factors. These factors include neural and chemical disturbances, changes in vascular calibre and elastance, cardiovascular reactivity, blood volume, and viscosity.14 in total In following years, Dr. Page made modifications to the Mosaic Theory in order to add more general terminology (Figure 2B),15 but the fundamental premise of his Mosaic Theory has remained unchanged up until the present day. Twenty-seven and seventeen The fact that the components of his Mosaic Theory embody a persistent primary discourse regarding the significance of the kidney (volume and cardiac output), the vasculature (elastance, vascular calibre, and reactivity), and the central nervous system (reactivity and neural function) is an intriguing aspect to take into consideration. The twenty years that have passed since the beginning of this century have brought about a great deal of progress in our understanding of the nodes that are shown in Figures 2A and 2B, as well as the introduction of completely new concepts. In order to get started, this review will first investigate well-known topics, such as the functions of the kidney, the vascular system, and the central nervous system, as well as the dominating role of aldosterone in hypertension. Following that, we will investigate innovative ideas that have surfaced over the course of the past twenty years. These are ideas that Dr. Page did not explore in his books, but which are likely to have an effect on each and every node in the Mosaic design. Other pages within this compendium delve into a variety of topics in greater depth than the ones that are discussed here.



Fig: 2 The original (A) and revised (B) Mosaic Theories proposed by Page.

## **Risk factor**

Despite the fact that there are certain findings that contradict each other, the overall conclusions that can be drawn from the chosen study are relatively comparable. Smoking, drinking alcohol, being overweight, having a family history of hypertension, getting older, eating a diet high in sodium, developing diabetes, and having a body mass index (BMI) that is higher than 30 kg/m2 are some of the major risk factors that might lead to the development of hypertension in young and middle-aged Indian adults. Research has discovered a number of factors that contribute to cardiovascular illness, including the waist-to-hip ratio, socioeconomic status, central obesity, increased cholesterol levels, physical inactivity, inadequate nutrition, insufficient exercise, lack of education, limited knowledge, and a history of cardiovascular disease. [47][48][49][50]

#### **Excessive Salt Intake**

A main factor that contributes to hypertension in both adults and the elderly is the use of an excessive amount of salt. [51][54]The existence of this risk factor was demonstrated by a large number of investigations that were analysed. Individuals who consume more than 10 grammes of salt on a daily basis are at an increased risk of developing hypertension, according to research that was carried out in a number of different geographical regions. An excessive consumption of salt was identified as a major risk factor in these studies (p<0.001) due to the fact that it was seen to be prevalent among the individuals who participated in the research. A study that was conducted in 2017 by Singh and colleagues found that the typical diet of Asians has a greater quantity of salt than the typical diet of Westerners. As a result of the rapid emergence of salt consumption as a substantial risk factor in the country, the Indian community will benefit from programs and awareness campaigns that are focused on reducing salt intake. [52][53]

### Alcohol Consumption, Tobacco, and Smoking

The intake of alcohol, the use of tobacco products, and smoking are the contemporary risk factors that are thought to be the most significant among adults.[54] Both drinking alcohol and smoking cigarettes are considered to be the most significant risk factors for young adults. In the research carried out, the p-value for smoking cigarettes was found to be 0.01, while the p-value for drinking alcohol was established to be 0.001.[56] Chewing tobacco was a behaviour that was observed to be prevalent among both male and female participants. According to the findings of

the study, it was found that smokers of any age, including adolescents and adults, were at an increased risk of developing hypertension when they used any kind of tobacco.

# **Obesity/BMI/Waist-to-Hip Ratio**

There are a number of risk factors that can lead to hypertension and other noncommunicable diseases. These risk factors include obesity, excess weight, a raised body mass index (BMI), and an increased waist-to-hip ratio.[57] The waist-to-hip ratio and the body mass index (BMI) are the usual measures that are used to determine whether or not an individual is overweight or obese. For young women, a high body mass index (BMI > 25 kg/m2) significantly increases the risk of developing hypertension, as evidenced by the research conducted A high body mass index (BMI) of more than 25 kg/m2 or an elevated waist-to-hip ratio (>0.85) was present in the majority of the patients who participated in the study, and sixty-eight percent of the participants were diagnosed with hypertension [58-60].

# **Diet and Physical Fitness**

The insufficient dietary patterns of the nation as well as the growing preference for fast food are both factors that contribute to the prevalence of hypertension. According to the findings of the research conducted by Bui Van et al. (2020) [61], the rising intake of oil and foods high in fat over the past several years may be a factor in the rise in the prevalence of obesity. The vast majority of people who have hypertension have a diet that is characterised by a high consumption of saturated fat and a low consumption of both protein and carbohydrates [62]. Based on the findings of the research conducted, it has been established that a decrease in the amount of fruits and vegetables consumed in one's diet is associated with an increase in hypertension. Some of the most important factors that contribute to the development of hypertension are lifestyle choices and a lack of adequate physical activity [63]. This study found that the majority of participants engaged in sedentary behaviours, consumed a significant amount of alcohol, smoked cigarettes on a regular basis, and consumed a limited amount of fruits and vegetables. Due to the fact that being overweight raises the probability of developing hypertension, a diet that is heavy in greasy and fatty foods, in conjunction with a reduction in physical activity and an absence of adequate exercise, can have a substantial impact on one's health. To prevent this from happening, educational initiatives concerning proper diet are absolutely necessary.

# **Family History**

Parents typically transmit their characteristics to their offspring over generations. Numerous diseases can be transmitted from parents to offspring. Their children may or may not be impacted by these diseases. The precise mechanism underlying this exchange is presently under investigation by researchers. Diseases can develop in offspring at any stage, with some appearing in infancy and others in old life. Hypertension is a heritable disorder, as stated [64]. Offspring of hypertensive parents exhibit a heightened predisposition to developing the ailment themselves. A child is at an elevated risk of getting hypertension if both parents have the condition and if the youngster encounters additional risk factors, including smoking, alcohol consumption, a high-fat diet, and a sedentary All patients in this study were adult males aged 20 to 49, with 58% exhibiting hypertension [65,66]. Obesity and familial history represented their most significant risk factors. This aligns with the familial associations between adiposity and hypertension. This research included numerous overweight and obese young women. Moreover, individuals possess a susceptibility to hypertension owing to a familial history of the condition. Familial hypertension is partially comprehended; nevertheless, additional research and details are necessary for comprehensive knowledge. Enhanced research and comprehension will enable us to eliminate the transmission of these diseases at their genetic origin, preserving numerous lives and averting innumerable impairments.

#### Sex

The relationship between sexual activity and blood pressure is complex and not easily discernible. It is widely acknowledged that there are considerable physiological, psychological, and hormonal differences in the functioning of male and female bodies. The research conducted by Mouhtadi et al. (2018) [67] demonstrated that hypertension predominantly impacts women. Patients with hypertension constituted 399 of the whole population. Given that the majority of rural women are homemakers, it is plausible that there is a higher prevalence of female hypertension among the Lebanese young adult population in whom this study was conducted. Their likelihood of developing hypertension escalates due to their sedentary lifestyle and seldom outdoor activity. These factors may significantly influence the increasing incidence of hypertension and other noncommunicable diseases (NCDs) in women [68]. Both AlWabel et al. (2018) [69] and Liu et al. (2017) [70] reported an elevated male-to-female ratio. Participants may

be responsible for the disproportionate representation of men in this research. Substance abuse and tobacco consumption were the most modifiable risk factors among the study participants. Tobacco and alcohol consumption is more prevalent among men in India. In male patients, these factors may have precipitated the development of hypertension [71,74]

## Illiteracy

The region of Varanasi in India was the location of the research that was carried out by Singh et al. (2017) [75]. There was a higher percentage of people living in urban areas who were illiterate, which was the most significant risk factor for hypertension. Illiteracy is widespread in India, which presents a significant challenge for the treatment of noncommunicable diseases like hypertension and other conditions. It is a contributing factor in the development of illiteracy, malnutrition, and acute and chronic health problems in a number of countries. In India and other developing nations, poverty and inadequate educational opportunities are widespread problems that need to be addressed.[76] There is a correlation between each of these variables and the probability of the others. There is a lack of uniformity and inadequate administration of the educational projects that are now being implemented by the government. The culture of male dominance is also responsible for the increased rate of illiteracy among women as well as their increased susceptibility to illness, as was proven in the previous section. If these diseases are adequately handled, the Indian populace may be able to benefit from increased enrolment opportunities in educational institutions. In order to reduce the incidence of disease and the rate of premature mortality, it is possible that addressing poverty and improving health literacy will be beneficial. [77]

#### **Socioeconomic Status**

The socioeconomic status of an individual is not only a risk factor for hypertension, but it also has the potential to be a driving force behind the condition. As stated by Singh et al. (2017) [78], the majority of people in India who suffer from hypertension are members of the middle class or the upper class themselves. These communities have a higher prevalence of noncommunicable diseases such as obesity, hypertension, and other obesity-related conditions. This hypertension class has an equal number of male and female participants who are at risk for the condition. Because many positions in the middle class and upper class entail little physical exertion, it is possible that these workers are at a greater risk than individuals with lesser incomes. [79] It is

also feasible that people who belong to higher socioeconomic categories have better health not only because they have access to better food but also because they have more quality leisure time. On the other hand, this may result in them gaining weight, which raises their chance of getting hypertension as well as other health concerns such as cardiovascular disease and stroke. Hypertension, on the other hand, is not a condition that is unique to individuals who have more funds. [80] The majority of people who fall into lower socioeconomic groups do not have access to diets that are high in nutrients and have insufficient understanding about hypertension. One of the potential causes of hypertension is an increase in salt consumption, which may be prevented by increasing the amount of fruits and vegetables that are consumed on a daily basis. Another potential cause is a deficiency in potassium in the diet. A further rise in their susceptibility is brought about by the absence of education and understanding regarding the risks associated with the illness.[81]

#### Strength and limitations

Furthermore, the search strategy that was described in the methodology section was exhaustive, despite the fact that there was a limitation of previous study on this subject.[82] The approach was followed in terms of the number of times that articles and evidence were evaluated, as well as the criteria that were utilised to determine who was included and who was not included. There were nevertheless significant flaws in the research, despite the fact that a considerable deal of attention was paid to minimising the likelihood of bias and maximising the reliability of the data. [84]The sample for the study consisted of young people between the ages of 18 and 50; nevertheless, there has been a dearth of research that specifically targets this age group, particularly in the field of hypertension and the risk factors and factors linked with it. It is probable that the conclusions of these studies do not apply to the entire population of India due to the fact that India is both a huge nation and a civilisation that is rich in diversity. Some of the studies that were looked at might have been defective since the inclusion and exclusion criteria were not explicit, the analyses were not clear, and the results were not obvious.[85]

#### New Trends in the Diagnosis and Management of Hypertension

Research incorporating human tissue samples from 15 organs has indicated that ACE2 is widely expressed, particularly in the heart and kidneys, as well as on the key target cells for SARS-CoV-2, namely the lung alveolar epithelial cells, which are the principal sites of damage. [86][87] 17

years old However, it is possible for it to be up-regulated in certain clinical situations. The levels of soluble ACE2 in circulation are relatively low, and its functional involvement in the lungs appears to be very insignificant under normal circumstances. When compared to the animal models that are currently available, there is a dearth of information in human subjects regarding the influence that RAAS inhibition has on the expression of ACE2. ACE inhibitors were administered intravenously to patients with coronary artery disease, and the results of the study showed that the injection did not have any effect on the production of angiotensin-(1-7). This finding raises questions about the direct impact that ACE inhibitors have on the metabolism of ACE2-mediated angiotensin II. There are thirty-five Following initial treatment with the ACE inhibitor captopril, patients with hypertension exhibited levels of angiotensin-1-7 that were unchanged.[88] However, after six months of captopril monotherapy, the levels of angiotensin-1-7 increased. This happened in a trial that was comparable to the one described above.36 In addition, there has been a limited amount of research conducted on the phenomenon of plasma ACE2 activity or urine ACE2 concentrations in individuals who are undergoing prolonged treatment with RAAS inhibitors. The plasma ACE2 activity of patients who were taking ACE inhibitors or ARBs was not found to be elevated in comparison to patients who were not receiving treatment in cross-sectional trials of individuals who were suffering from heart failure, atrial fibrillation, aortic stenosis, and coronary artery disease. The urinary ACE2 levels of Japanese patients with hypertension who were receiving long-term treatment with the ARB olmesartan were found to be higher than those of untreated control patients, according to the findings of a longitudinal cohort study. On the other hand, this association was not observed with the ACE inhibitor enalapril or with other ARBs (losartan, candesartan, valsartan, and telmisartan).[89][90]

# **Blood Pressure targets**

Regarding the diagnosis and treatment of hypertension, there are a great number of guidelines available on both the national and international levels. There is a lack of agreement among members of the guidelines regarding the definition of hypertension and the treatment goals for blood pressure (BP). The guidelines that were released by the American College of Cardiology and the American Heart Association in 2018 are garnering a significant amount of support and endorsement from professional groups [91]. They are mostly based on the SPRINT as its

foundation. According to these standards, a normal blood pressure (BP) reading is defined as a systolic blood pressure (SBP) that is lower than 120 mm Hg and a diastolic blood pressure (DBP) that is lower than 80 mm Hg. A systolic blood pressure (SBP) that falls within the range of 120 to 129 mm Hg and a diastolic blood pressure (DBP) that falls below 80 mm Hg are included in the definition of elevated blood pressure. There are two stages of hypertension: stage 1, which is defined by a blood pressure reading of 130-139 mm Hg or a blood pressure reading of 80-89 mm Hg; and stage 2, which is defined by a blood pressure reading of 140 mm Hg or higher or a blood pressure reading of 90 mm Hg or higher. In order to get a precise diagnosis of hypertension, it is necessary to obtain a minimum of two readings of blood pressure during two distinct visits. According to the standards, the ideal blood pressure target is one that is lower than 130/80 mm Hg. Patients with comorbidities, such as stable ischaemic heart disease, diabetes mellitus, and chronic kidney disease (CKD), continue to experience this aim in the same manner. Patients who are experiencing acute intracerebral haemorrhage or acute ischaemic stroke are not eligible for this objective. After the revised ACC/AHA definition of hypertension was implemented, there has been an increase in the number of people who are diagnosed with hypertension around the world. In the United States, the prevalence of hypertension has increased by 13.7%, affecting more than 31 million people. This is a rise from 32% to 45.6%. It was the age group between 20 and 44 years old that experienced the most dramatic impact, with the prevalence increasing from around 11% to 24%. [91-92]

# **SPRINT**

Hypertension is a significant public health issue due to its prevalence and its status as a primary risk factor for various illnesses, including myocardial infarction, heart failure, cerebrovascular accident, chronic renal disease, and cognitive deterioration. The NIH Systolic Blood Pressure Intervention Trial (SPRINT), financed by the NHLBI, seeks to address three critical research enquiries regarding the impact of reducing systolic blood pressure to below 120 millimetres of mercury (mm Hg) on the cardiovascular system, kidneys, and brain.[92,93]

• Cardiovascular: The primary research inquiry in SPRINT was to ascertain whether managing high blood pressure to a target systolic goal of less than 120 mm Hg was superior to a target of less than 140 mm Hg, the standard recommendation at the study's inception. At the time of

SPRINT's conception, observational studies indicated that participants with reduced systolic blood pressure levels experienced fewer problems and fatalities related to cardiovascular illnesses. The advantages and possible adverse consequences of managing individuals without a prior history of diabetes or stroke to a systolic blood pressure below 120 mm Hg, as contrast to a target of below 140 mm Hg, have not been evaluated in a long-term clinical research. • Kidneys: SPRINT enrolled people with chronic kidney illness to evaluate the impact of a reduced systolic blood pressure target on their cardiovascular and renal function. SPRINT Memory and Cognition in Decreased Hypertension (SPRINT-MIND) investigates whether targeting lower blood pressure reduces the risk of dementia, slows cognitive decline, and results in diminished small vessel disease in the brain as evidenced by magnetic resonance imaging (MRI).

#### **Treatment & Management**

In a number of countries, primary care physicians are being encouraged to take on the role of the primary healthcare providers responsible for the identification, prevention, and management of cardiovascular risk factors. In spite of this, the majority of countries with low incomes have an inadequate number of medical professionals, particularly in rural and remote locations. It is thirty. A number of strategies, such as task-sharing and shifting, which involve assigning less complex responsibilities to non-physician health professionals under the supervision of a physician, have proven to be effective in alleviating severe barriers to improving hypertension control. It is five The black barbershop trial is an example of health promotion practices that have been endorsed by trusted members of the community. In this trial, healthcare evaluations and prescriptions were moved from healthcare facilities to the community, which resulted in a significant reduction of systolic blood pressure (approximately 20 mmHg). This was in comparison to the active encouragement of lifestyle modifications and doctor appointments by barbers. [94] Multidisciplinary preventive cardiovascular programs have been formed in a number of countries for the purpose of assessing and managing cardiovascular risk. These programs also include the treatment of risk factors such as hypertension. The presence of hypertension, along with other risk factors such as dyslipidaemia, obesity, diabetes, or smoking, considerably increases the likelihood of cardiovascular disease. All of the additional risk factors that are linked with metabolic syndrome must be corrected in addition to hypertension, which is

present in eighty percent of cases. This is because metabolic syndrome poses a considerable threat. There are thirty-two hypertension management strategies that ought to be incorporated into complete cardiovascular risk reduction. [95]

# **Pharmacological interventions**

Pharmacological control of hypertension is an essential component in the therapy of the condition. Seventh When it comes to the treatment of hypertension, numerous medications have been developed and shown to be effective. Seventh It is important to note that the utilisation of antihypertensive medication differs greatly across the world's regions. 33rd Antihypertensive medication is used more frequently in regions with high incomes than in regions with moderate or low incomes, with the percentage of people who use it being 56% versus 29%. According to the findings of the Prospective Urban Rural Epidemiology (PURE) study, the overall control was found to be the lowest in countries with low and lower-middle incomes (11%), in contrast to countries with high incomes (19%) and countries with upper-middle incomes (16%). [96] Among the factors that contributed to the insufficient treatment and regulation of hypertension were the utilisation of therapy that was less than ideal and restricted access to the healthcare system. Due to the fact that low-dose combinations of antihypertensive agents demonstrate superior efficacy in blood pressure reduction and tolerability in comparison to high-dose monotherapies, the HTN recommendations advocate for the initial use of low-dose pharmacological therapy. This is followed by titration and/or the incorporation of additional medications depending on the patient's tolerability and the blood pressure that has been achieved. Seventh In light of the fact that the majority of patients will require two or more prescriptions in order to achieve their blood pressure goals, it is recommended that a combination of medications that are taken in a single pill at decreased dosages be utilised. This may improve adherence, performance, and tolerance to treatment. Seventh The World Health Organisation (WHO) published a list of essential medicines in 2019, which included single-pill antihypertensive drug combinations. a 34 There are currently single-pill combos available that contain two or three different antihypertensive medications currently on the market. [97]

# **Patient empowerment**

There is a significant amount of difference in the perception of hypertension around the world. Sixty-seven percent of people in high-income countries have it, compared to thirty-eight percent of people in low- or middle-income countries. [98]- A holistic, individual-focused strategy that empowers a wider demography, including patients, families, networks, and society, should be considered an effective method to promote adherence to self-care and therapy alternatives in hypertension control. This strategy should be viewed as an effective method. An crucial method for improving hypertension management in primary care settings is to educate both patients and the caretakers who are responsible for their care. It is five For the purpose of encouraging patients to take an active role in the formation of treatment goals, it is necessary to inform patients about their blood pressure aims. A substantial body of data suggests that selfmonitoring blood pressure, particularly when done within the context of a comprehensive intervention framework (which may include counselling, telephone support, or telemonitoring), has the potential to enhance treatment adherence and promote optimal blood pressure control. Forty-nine and forty years. Innovative and cutting-edge tools. New prospects for improving hypertensive care are made available by technological advancements in the medical field, namely in the areas of digital health and telemedicine.[98][99] It is five Patients are able to measure their blood pressure (BP) at home and electronically transmit the results to the clinical care team. The clinical care team can then make recommendations for changes in lifestyle, modifications to medication, or appointment arrangements. Telemonitoring encompasses more than just self-monitoring of blood pressure (BP). This feedback loop has the potential to improve patient engagement in care, reduce instances of unnecessary office visits, and provide assistance in the management of hypertension; however, it is contingent upon the implementation of secure mechanisms for the exchange of data between clinical and community settings. The number 42 Within the context of a comprehensive management framework, the World Health Organisation (WHO) supports the development of home-based self-care and telemonitoring as a means of improving blood pressure regulation.[100] a The results of the HOME BP and HERB-DH1 trials demonstrated that digital applications, which include interactive education, digital support for nonpharmacological interventions, and self-planning and evaluation tools, had a significant impact on lowering systolic blood pressure by 3.4 mmHg (HOME BP) and 3.6 mmHg (HERB-DH1) respectively. This demonstrates that innovative technologies are not only feasible and effective, but also have a minimal incremental cost.

# Conclusion

Heart disease, stroke, renal damage, and other health difficulties can be considerably increased by hypertension, also known as high blood pressure. Hypertension is a frequent and serious condition that can significantly increase the risk of these conditions. When it comes to preventing these dangers, early detection and management are absolutely essential. Modifications to one's lifestyle, such as engaging in regular physical activity, maintaining a balanced diet, minimising the amount of salt consumed, limiting the amount of alcohol consumed, and managing stress, are vital for controlling one's blood pressure. Medication may be required in certain circumstances in order to assist in maintaining a blood pressure that is within a healthy range. In order to effectively manage hypertension and improve long-term health outcomes, it is essential to adopt a proactive treatment approach and to do regular monitoring tests. Individuals can lower their risk of problems and lead healthier lives if they take action to manage hypertension at an early stage and adhere to the lifestyle changes or treatments that are advised.

#### References

- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2018;138(17):1–17. Oct 23 doi: 10.1161/CIR.000000000000597.
- Feigin VL, Norrving B, Mensah GA.. Global burden of stroke. Circ Res. 2017;120(3):439–448. doi: 10.1161/CIRCRESAHA.116.308413.
- O'Donnell MJ, Xavier D, Liu L, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010;376(9735):112–123. doi: 10.1016/S0140-6736(10)60834-3
- Carrick D, Haig C, Maznyczka AM, et al. Hypertension, microvascular pathology, and prognosis after an acute myocardial infarction. Hypertension. 2018;72(3):720–730. doi: 10.1161/HYPERTENSIONAHA.117.10786

- Psaty BM, Furberg CD, Kuller LH, et al. Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality: the cardiovascular health study. Arch Intern Med. 2001;161(9):1183–1192. doi: 10.1001/archinte.161.9.1183.
- Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JAMA. 1996;275(20):1557–1562. doi: 10.1001/jama.1996.03530440037034
- Bidani AK, Griffin KA.. Pathophysiology of hypertensive renal damage: implications for therapy. Hypertension. 2004;44(5):595–601. Nov doi: 10.1161/01.HYP.0000145180.38707.84.
- Danaei G, Ding EL, Mozaffarian D, et al. The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLOS Med. 2009;6(4):e1000058. doi: 10.1371/journal.pmed.1000058
- 9. Data from: National Center for Health Statistics, Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey (NHANES) . 2015–2018
- Zhou B, Carrillo-Larco RM, Danaei G, et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957–980. doi: 10.1016/S0140-6736(21)01330-1
- Rossi GP, Bisogni V, Rossitto G, et al. Practice recommendations for diagnosis and treatment of the most common forms of secondary hypertension. High Blood Press Cardiovasc Prev. 2020;27(6):547–560. Dec doi: 10.1007/s40292-020-00415-9
- Taler, SJ. Secondary causes of hypertension. Prim Care Clin Office Pract. 2008;35(3):489– 500. doi: 10.1016/j.pop.2008.06.001.
- 13. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of cardiology and the European society of hypertension: the task force for the management of arterial hypertension of the European society of cardiology and the European society of hypertension. J Hypertens. 2018;36(10):1953–2041. doi: 10.1097/HJH.0000000000001940

- Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA.2003;289(19):2560–2572. doi: 10.1001/jama.289.19.2560
- 15. Garies S, Hao S, McBrien K, et al. Prevalence of hypertension, treatment, and blood pressure targets in Canada associated with the 2017 American college of cardiology and American heart association blood pressure guidelines. JAMA Netw Open. 2019;2(3):e190406. doi: 10.1001/jamanetworkopen.2019.0406.
- 16. de la Sierra A. New American and european hypertension guidelines, reconciling the differences. Cardiol Ther. 2019;8(2):157–166. doi: 10.1007/s40119-019-0144-3.
- Zhang W, Zhang S, Deng Y, et al. Trial of intensive blood-pressure control in older patients with hypertension. N Engl J Med. 2021;385(14):1268–1279. doi: 10.1056/NEJMoa2111437
- Rabi DM, McBrien KA, Sapir-Pichhadze R, et al. Hypertension Canada's 2020 comprehensive guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children. Can J Cardiol. 2020;36(5):596–624. doi: 10.1016/j.cjca.2020.02.086
- Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575–1585. doi: 10.1056/NEJMoa1001286
- Wright JT, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–2116. doi: 10.1056/NEJMoa1511939.
- Drawz PE, Ix JH.. BP measurement in clinical practice: time to SPRINT to guidelinerecommended protocols. J Am Soc Nephrol. 2018;29(2):383–388. Feb doi: 10.1681/ASN.2017070753.
- Stergiou GS, Palatini P, Parati G, et al. 2021 European society of hypertension practice guidelines for office and out-of-office blood pressure measurement. J Hypertens. 2021;39(7):1293–1302. doi: 10.1097/HJH.000000000002843

- McManus RJ, Mant J, Franssen M, et al. Efficacy of self-monitored blood pressure, with or without telemonitoring, for titration of antihypertensive medication (TASMINH4): an unmasked randomised controlled trial. Lancet. 2018;391(10124):949–959. doi: 10.1016/S0140-6736(18)30309-X
- Velasquez MT, Beddhu S, Nobakht E, et al. Ambulatory blood pressure in chronic kidney disease: ready for prime time? Kidney Int Rep. 2016;1(2):94–104. doi: 10.1016/j.ekir.2016.05.001.
- 25. Kim CS, Choi HS, Bae EH, et al. Optimal blood pressure target and measurement in patients with chronic kidney disease. Korean J Intern Med. 2019;34(6):1181–1187.v doi: 10.3904/kjim.2019.164.
- 26. Kanno A, Kikuya M, Asayama K, et al. Night-time blood pressure is associated with the development of chronic kidney disease in a general population: the ohasama study. J Hypertens. 2013;31(12):2410–2417. doi: 10.1097/HJH.0b013e328364dd0f.
- Yang WY, Melgarejo JD, Thijs L, et al. Association of office and ambulatory blood pressure with mortality and cardiovascular outcomes. JAMA. 2019;322(5):409–420. doi: 10.1001/jama.2019.9811.
- Parati G, Ochoa JE, Salvi P, et al. Prognostic value of blood pressure variability and average blood pressure levels in patients with hypertension and diabetes. Diabetes Care. 2013;36 Suppl 2(Suppl 2):S312–S24. doi: 10.2337/dcS13-2043.
- Pickering TG, Shimbo D, Haas D.. Ambulatory blood-pressure monitoring. N Engl J Med. 2006;354(22):2368–2374. doi: 10.1056/NEJMra060433
- Shang W, Zhang Y, Liu L, et al. Benefits of continuous positive airway pressure on blood pressure in patients with hypertension and obstructive sleep apnea: a meta-analysis. Hypertens Res. 2022;45(11):1802–1813. doi: 10.1038/s41440-022-00954-9.
- 31. Campbell NRC, Paccot Burnens M, Whelton PK, et al. 2021 World health organization guideline on pharmacological treatment of hypertension: policy implications for the region of the Americas. Lancet Reg Health Am. 2022;9: none. doi: 10.1016/j.lana.2022.100219.

- 32. Hall JE. The kidney, hypertension, and obesity. Hypertension. 2003;41(3 Pt 2):625-633. doi: 10.1161/01.HYP.0000052314.95497.78.
- Jones DW, Kim JS, Andrew ME, et al. Body mass index and blood pressure in Korean men and women: the Korean National blood pressure survey. J Hypertens. 1994;12(12):1433– 1437. doi: 10.1097/00004872-199412000-00018.
- Garrison RJ, Kannel WB, Stokes J, 3rd, et al. Incidence and precursors of hypertension in young adults: the Framingham offspring study. Prev Med. 1987;16(2):235–251. doi: 10.1016/0091-7435(87)90087-9
- 35. Weiss EP, Albert SG, Reeds DN, et al. Effects of matched weight loss from calorie restriction, exercise, or both on cardiovascular disease risk factors: a randomized intervention trial. Am J Clin Nutr. 2016;104(3):576–586. doi: 10.3945/ajcn.116.131391.
- 36. Garvey WT, Mechanick JI, Brett EM, et al. American association of clinical endocrinologists and American college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22 Suppl 3:1–203. Jul doi: 10.4158/EP161365.GL
- Jebb SA, Ahern AL, Olson AD, et al. Primary care referral to a commercial provider for weight loss treatment versus standard care: a randomised controlled trial. Lancet. 2011;378(9801):1485–1492. doi: 10.1016/S0140-6736(11)61344-5.
- 38. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts)developed with the special contribution of the European association for cardiovascular prevention & rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315–2381. doi: 10.1093/eurheartj/ehw106.
- Cornelissen VA, Smart NA.. Exercise training for blood pressure: a systematic review and meta-analysis. J Am Heart Assoc. 2013;2(1):e004473. doi: 10.1161/JAHA.112.004473

- 40. MacDonald HV, Johnson BT, Huedo-Medina TB, et al. Dynamic resistance training as stand-alone antihypertensive lifestyle therapy: a meta-analysis. J Am Heart Assoc. 2016;5(10):e003231. doi: 10.1161/JAHA.116.003231
- 41. Sosner P, Guiraud T, Gremeaux V, et al. The ambulatory hypotensive effect of aerobic training: a reappraisal through a meta-analysis of selected moderators. Scand J Med Sci Sports. 2017;27(3):327–341. Mar doi: 10.1111/sms.12661.
- 42. Williams MA, Haskell WL, Ades PA, et al. Resistance exercise in individuals with and without cardiovascular disease: 2007 update: a scientific statement from the American heart association council on clinical cardiology and council on nutrition, physical activity, and metabolism. Circulation. 2007;116(5):572–584. doi: 10.1161/CIRCULATIONAHA.107.185214.
- 43. Naci H, Salcher-Konrad M, Dias S, et al. How does exercise treatment compare with antihypertensive medications? A network meta-analysis of 391 randomised controlled trials assessing exercise and medication effects on systolic blood pressure. Br J Sports Med. 2019;53(14):859–869. doi: 10.1136/bjsports-2018-099921
- 44. Costa EC, Hay JL, Kehler DS, et al. Effects of high-intensity interval training versus moderate-intensity continuous training on blood pressure in adults with pre- to established hypertension: a systematic review and meta-analysis of randomized trials. Sports Med. 2018;48(9):2127–2142. Sep doi: 10.1007/s40279-018-0944-y.
- 45. Psaltopoulou T, Naska A, Orfanos P, et al. Olive oil, the mediterranean diet, and arterial blood pressure: the greek European prospective investigation into cancer and nutrition (EPIC) study. Am J Clin Nutr. 2004;80(4):1012–1018. doi: 10.1093/ajcn/80.4.1012.
- 46. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. DASH-sodium collaborative research group. N Engl J Med. 2001;344(1):3–10. doi: 10.1056/NEJM200101043440101

- Gay HC, Rao SG, Vaccarino V, et al. Effects of different dietary interventions on blood pressure: systematic review and meta-analysis of randomized controlled trials. Hypertension. 2016;67(4):733–739. doi: 10.1161/HYPERTENSIONAHA.115.06853.
- 48. Esposito K, Kastorini CM, Panagiotakos DB, et al. Mediterranean diet and weight loss: meta-analysis of randomized controlled trials. Metab Syndr Relat Disord. 2011;9(1):1–12. doi: 10.1089/met.2010.0031
- Hall ME, Cohen JB, Ard JD, et al. Weight-Loss strategies for prevention and treatment of hypertension: a scientific statement from the American heart association. Hypertension. 2021;78(5):e38–e50. doi: 10.1161/HYP.000000000002022.
- Graudal N, Hubeck-Graudal T, Jurgens G, et al. Dose-response relation between dietary sodium and blood pressure: a meta-regression analysis of 133 randomized controlled trials. Am J Clin Nutr. 2019;109(5):1273–1278. doi: 10.1093/ajcn/nqy384.
- Huang L, Trieu K, Yoshimura S, et al. Effect of dose and duration of reduction in dietary sodium on blood pressure levels: systematic review and meta-analysis of randomised trials. BMJ. 2020;368:m315. doi: 10.1136/bmj.m315
- Unger T, Borghi C, Charchar F, et al. 2020 International society of hypertension global hypertension practice guidelines. Hypertension. 2020;75(6):1334–1357. doi: 10.1161/HYPERTENSIONAHA.120.15026.
- 53. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2224–2260. doi: 10.1016/S0140-6736(12)61766-8.
- Lundbäck M, Antoniewicz L, Brynedal A, et al. Acute effects of active e-cigarette inhalation on arterial stiffness. Eur Respir J. 2017;50(61) OA1979. doi: 10.1183/1393003.congress-2017
- 55. Tattersall MC, Hughey CM, Piasecki TM, et al. Abstract 11674: acute effects of nicotinecontaining product challenges on cardiovascular and autonomic function among electronic

cigarette vapers, combustible cigarette smokers, and controls: the CLUES study. Circulation. 2022;146:A11674. doi: 10.1161/circ.146.suppl 1.11674Circulation.

- 56. Vlachopoulos C, Ioakeimidis N, Abdelrasoul M, et al. Electronic cigarette smoking increases aortic stiffness and blood pressure in young smokers. J Am Coll Cardiol. 2016;67(23):2802–2803. doi: 10.1016/j.jacc.2016.03.569.
- 57. Peruzzi M, Biondi-Zoccai G, Carnevale R, et al. Vaping cardiovascular health risks: an updated umbrella review. Curr Emerg Hosp Med Rep. 2020;8(3):103–109. doi: 10.1007/s40138-020-00219-0.
- 58. Miller CR, Shi H, Li D, et al. Cross-Sectional associations of smoking and E-cigarette use with self-Reported diagnosed hypertension: findings from wave 3 of the population assessment of tobacco and health study. Toxics. 2021;9(3):52. doi: 10.3390/toxics9030052
- 59. Parati G, Kjeldsen S, Coca A, et al. Adherence to single-pill versus free-equivalent combination therapy in hypertension: a systematic review and meta-analysis. Hypertension. 2021;77(2):692–705. doi: 10.1161/HYPERTENSIONAHA.120.15781.
- 60. Volpe M, Gallo G, Tocci G. New approach to blood pressure control: triple combination pill. Trends Cardiovasc Med. 2020;30(2):72–77. doi: 10.1016/j.tcm.2019.03.002.
- 61. Chow CK, Atkins ER, Hillis GS, et al. Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial. Lancet. 2021;398(10305):1043–1052. doi: 10.1016/S0140-6736(21)01922-X.
- 62. Webster R, Salam A, de Silva HA, et al. Fixed low-dose triple combination antihypertensive medication vs usual care for blood pressure control in patients with mild to moderate hypertension in Sri Lanka: a randomized clinical trial. JAMA. 2018;320(6):566–579. doi: 10.1001/jama.2018.10359.
- Carey RM, Calhoun DA, Bakris GL, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American heart association. Hypertension. 2018;72(5):e53–e90. Nov doi: 10.1161/HYP.000000000000084.

- 64. Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386(10008):2059–2068. doi: 10.1016/S0140-6736(15)00257-3
- Lauder L, Mahfoud F, Azizi M, et al. Hypertension management in patients with cardiovascular comorbidities. Eur Heart J. 2023;44(23):2066–2077. doi: 10.1093/eurheartj/ehac395.
- Akbari P, Khorasani-Zadeh A. Thiazide Diuretics. [Updated 2023 Jan 23]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available from: <u>https://www.ncbi.nlm.nih.gov/books/NBK532918/</u>
- 67. Olde Engberink RH, Frenkel WJ, van den Bogaard B, et al. Effects of thiazide-type and thiazide-like diuretics on cardiovascular events and mortality: systematic review and meta-analysis. Hypertension. 2015;65(5):1033–1040. doi: 10.1161/HYPERTENSIONAHA.114.05122.
- Ishani A, Cushman WC, Leatherman SM, et al. Chlorthalidone vs. hydrochlorothiazide for hypertension-cardiovascular events. N Engl J Med. 2022;387(26):2401–2410. doi: 10.1056/NEJMoa2212270.
- Ishani A, Cushman WC, Leatherman SM.. Chlorthalidone vs. hydrochlorothiazide for hypertension-cardiovascular events. Reply. N Engl J Med. 2023;388(14):1342. Apr 6 doi: 10.1056/NEJMc2301922.
- Chaaban N, Kshatriya S.. Thiazide-induced pancreatitis. Kans J Med. 2022;15(2):220–221. doi: 10.17161/kjm.vol15.16534.
- 71. Martins VM, Ziegelmann PK, Ferrari F, et al. Thiazide diuretics alone or combined with potassium-sparing diuretics to treat hypertension: a systematic review and network metaanalysis of randomized controlled trials. J Hypertens. 2023;41(7):1108–1116. doi: 10.1097/HJH.000000000003436

- 72. Teles F, Peçanha de Miranda Coelho JA, Albino RM, et al. Effectiveness of thiazide and thiazide-like diuretics in advanced chronic kidney disease: a systematic review and metaanalysis. Ren Fail. 2023;45(1):2163903. doi: 10.1080/0886022X.2022.2163903.
- Agarwal R, Sinha AD, Cramer AE, et al. Chlorthalidone for hypertension in advanced chronic kidney disease. N Engl J Med. 2021;385(27):2507–2519. doi: 10.1056/NEJMoa2110730.
- Feig PU. Cellular mechanism of action of loop diuretics: implications for drug effectiveness and adverse effects. Am J Cardiol. 1986;57(2):14A–19A. doi: 10.1016/0002-9149(86)91001-5.
- Weir MR, Dzau VJ. The renin-angiotensin-aldosterone system: a specific target for hypertension management. Am J Hypertension. 1999;12(S9):205S–213S. doi: 10.1016/S0895-7061(99)00103-X.
- 76. Chen R, Suchard MA, Krumholz HM, et al. Comparative first-line effectiveness and safety of ACE (angiotensin-converting enzyme) inhibitors and angiotensin receptor blockers: a multinational cohort study. Hypertension. 2021;78(3):591–603. doi: 10.1161/HYPERTENSIONAHA.120.16667.
- Piepho RW. Overview of the angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm. 2000;57(Suppl 1):S3–S7. doi: 10.1093/ajhp/57.suppl\_1.S3
- Burnakis TG, Mioduch HJ.. Combined therapy with captopril and potassium supplementation. A potential for hyperkalemia. Arch Intern Med. 1984;144(12):2371– 2372.
- Khosla S, Ahmed A, Siddiqui M, et al. Safety of angiotensin-converting enzyme inhibitors in patients with bilateral renal artery stenosis following successful renal artery stent revascularization. Am J Ther. 2006;13(4):306–308. doi: 10.1097/00045391-200607000-00005.
- Lunde H, Hedner T, Samuelsson O, et al. Dyspnoea, asthma, and bronchospasm in relation to treatment with angiotensin converting enzyme inhibitors. BMJ. 1994;308(6920):18–21. doi: 10.1136/bmj.308.6920.18.

- Israili ZH, Hall WD.. Cough and angioneurotic edema associated with angiotensinconverting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med. 1992;117(3):234–242. doi: 10.7326/0003-4819-117-3-234.
- Overlack A. ACE inhibitor-induced cough and bronchospasm. Incidence, mechanisms and management. Drug Saf. 1996;15(1):72–78. doi: 10.2165/00002018-199615010-00006.
- Kronish IM, Woodward M, Sergie Z, et al. Meta-analysis: impact of drug class on adherence to antihypertensives. Circulation. 2011;123(15):1611–1621. doi: 10.1161/CIRCULATIONAHA.110.983874.
- Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–1559. doi: 10.1056/NEJMoa0801317
- 85. Helmer A, Slater N, Smithgall S.. A review of ACE inhibitors and ARBs in black patients with hypertension. Ann Pharmacother. 2018;52(11):1143–1151. doi: 10.1177/1060028018779082
- Williams SF, Nicholas SB, Vaziri ND, et al. African Americans, hypertension and the renin angiotensin system. World J Cardiol. 2014;6(9):878–889. doi: 10.4330/wjc.v6.i9.878.
- Palla M, Ando T, Androulakis E, et al. Renin-Angiotensin system inhibitors vs other antihypertensives in hypertensive blacks: a meta-analysis. J Clin Hypertens 2017;19(4):344–350. doi: 10.1111/jch.12867
- Triggle DJ. The physiological and pharmacological significance of cardiovascular T-type, voltage-gated calcium channels. Am J Hypertens. 1998;11(4):80S–87S. doi: 10.1016/s0895-7061(98)00004-1.
- Nathan S, Pepine CJ, Bakris GL.. Calcium antagonists: effects on cardio-renal risk in hypertensive patients. Hypertension. 2005;46(4):637–642. doi: 10.1161/01.HYP.0000184541.24700.c7.
- Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957–967. Mar 5 doi: 10.1016/S0140-6736(15)01225-8.

- 91. Thomopoulos C, Parati G, Zanchetti A.. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs overview and meta-analyses. J Hypertens. 2015;33(7):1321–1341. doi: 10.1097/HJH.00000000000614
- 92. S, Sherpa LY, Sepehry AA, et al. Effects of long- and Intermediate-Acting dihydropyridine calcium channel blockers in hypertension: a systematic review and meta-analysis of 18 prospective, randomized, actively controlled trials. J Cardiovasc Pharmacol Ther. 2018;23(5):433–445. doi: 10.1177/1074248418771341.
- Kubota K, Pearce GL, Inman WH.. Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring. Eur J Clin Pharmacol. 1995;48(1):1–7. doi: 10.1007/BF00202163.
- 94. Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart rhythm society. Circulation. 2019;140(8):e382–e482. doi: 10.1161/CIR.00000000000628
- Opie LH. Calcium channel antagonists. Part IV: side effects and contraindications drug interactions and combinations. Cardiovasc Drugs Ther. 1988;2(2):177–189. doi: 10.1007/BF00051233.
- 96. Farzam K, Jan A. Beta Blockers. [Updated 2023 Aug 22]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK532906
- 97. Wiysonge CS, Bradley HA, Volmink J, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2017;1(1):CD002003. doi: 10.1002/14651858.CD002003.pub5.
- 98. .Khan N, McAlister FA.. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ. 2006;174(12):1737–1742. doi: 10.1503/cmaj.060110

- 99. Podymow T, August P.. Update on the use of antihypertensive drugs in pregnancy. Hypertension. 2008;51(4):960–969. doi: 10.1161/HYPERTENSIONAHA.106.075895.
- 100.Brown CM, Garovic VD.. Drug treatment of hypertension in pregnancy. Drugs. 2014;74(3):283–296. doi: 10.1007/s40265-014-0187-7